KRAS and neoplasm: The upcoming STEM-VAC, 1503TiP, and SLATE-KRAS clinical trials hold particular interest as multiple, high quality, tumor antigens were included in each formulation, and an impressive trial design will allow the benefits of vaccination alone to be derived.